首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1235508篇
  免费   79830篇
  国内免费   1703篇
耳鼻咽喉   17213篇
儿科学   39285篇
妇产科学   32465篇
基础医学   176394篇
口腔科学   34885篇
临床医学   104320篇
内科学   240095篇
皮肤病学   28981篇
神经病学   94575篇
特种医学   47020篇
外国民族医学   203篇
外科学   182315篇
综合类   22487篇
现状与发展   1篇
一般理论   290篇
预防医学   93223篇
眼科学   28808篇
药学   98450篇
  7篇
中国医学   3453篇
肿瘤学   72571篇
  2021年   9963篇
  2019年   10528篇
  2018年   16235篇
  2017年   11933篇
  2016年   13137篇
  2015年   14685篇
  2014年   18988篇
  2013年   27891篇
  2012年   40672篇
  2011年   43109篇
  2010年   24215篇
  2009年   21605篇
  2008年   38828篇
  2007年   41546篇
  2006年   41911篇
  2005年   39856篇
  2004年   37903篇
  2003年   36212篇
  2002年   34844篇
  2001年   64829篇
  2000年   66987篇
  1999年   55075篇
  1998年   13167篇
  1997年   11459篇
  1996年   11467篇
  1995年   10708篇
  1994年   9665篇
  1993年   9126篇
  1992年   39853篇
  1991年   38103篇
  1990年   37495篇
  1989年   35831篇
  1988年   32325篇
  1987年   31303篇
  1986年   29591篇
  1985年   27738篇
  1984年   20095篇
  1983年   16906篇
  1982年   9269篇
  1979年   18096篇
  1978年   12135篇
  1977年   10921篇
  1976年   9489篇
  1975年   10877篇
  1974年   12672篇
  1973年   12331篇
  1972年   11778篇
  1971年   11063篇
  1970年   10167篇
  1969年   9930篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
82.
83.
The aim of the present study was to evaluate the antimicrobial activity of two synbiotic combinations, Lactobacillus fermentum with short-chain fructooligosaccharides (FOS-LF) and Bifidobacterium longum with isomaltooligosaccharides (IMO-BL), against enterohaemorrhagic Escherichia coli O157:H7 and enteropathogenic E. coli O86. Antimicrobial activity was determined (1) by co-culturing the synbiotics and pathogens in batch cultures, and (2) with the three-stage continuous culture system (gut model), inoculated with faecal slurry from an elderly donor. In the co-culture experiments, IMO-BL was significantly inhibitory to both E. coli strains, while FOS-LF was slightly inhibitory or not inhibitory. Factors other than acid production appeared to play a role in the inhibition. In the gut models, both synbiotics effectively inhibited E. coli O157 in the first vessel, but not in vessels 2 and 3. E. coli O86 was not significantly inhibited.  相似文献   
84.
85.
86.
87.

Objective

Arch obstruction after the Norwood procedure is common and contributes to mortality. We determined the prevalence, associated factors, and practice variability of arch reintervention and assessed whether arch reintervention is associated with mortality.

Methods

From 2005 to 2017, 593 neonates in the Congenital Heart Surgeons' Society Critical Left Heart Obstruction cohort underwent a Norwood procedure. Median follow-up was 3.7 years. Multivariable parametric models, including a modulated renewal analysis, were performed.

Results

Of the 593 neonates, 146 (25%) underwent 218 reinterventions for arch obstruction after the Norwood procedure: catheter-based (n = 168) or surgical (n = 50) at a median age of 4.3 months (quartile 1-quartile 3, 2.6-5.7). Interdigitation of the distal aortic anastomosis was protective against arch reintervention. Development of ≥ moderate tricuspid valve regurgitation and right ventricular dysfunction at any point was associated with arch reintervention. Nonsignificant variables for arch reintervention included shunt type and preoperative aortic measurements. Surgical arch reintervention was protective against arch reintervention, but transcatheter reintervention was associated with increased reintervention. Arch reintervention was not associated with increased mortality. There was wide institutional variation in incidence of arch reintervention (range, 0-40 reinterventions per 100 years patient follow-up) and in preintervention gradient (range, 0-64 mm Hg).

Conclusions

Interdigitation of the distal aortic anastomosis during the Norwood procedure decreased the risk of arch reintervention. Surgical arch reintervention is more definitive than transcatheter. Arch reintervention after the Norwood procedure is not associated with increased mortality. Serial surveillance for arch obstruction, integrated with changes in right ventricular function and tricuspid valve regurgitation, is recommended after the Norwood procedure to improve outcomes.  相似文献   
88.

Background

Since recent reports have shown that (-)-Epigallocatechin-3-gallate (EGCG) could be used for treating proliferative and inflammatory disorders, we explored its use for the management of corneal chemical burns.

Materials and methods

Initially, EGCG was assayed on the rabbit corneal epithelial cell line RCE1(5T5) to establish the best testing conditions, and to avoid unwanted outcomes in the experimental animals. Then, we studied its effects on cell proliferation, cell cycle progression and cell differentiation. Afterwards, we instilled EGCG in experimental grade II corneal alkali burns in mice, three times a day up to 21 days, and evaluated by slit lamp examination and histological sections of corneal epithelial, corneal endothelial and stromal edema, as well as the presence of inflammatory cells and neovascularization.

Results

EGCG reduced cell growth and led to a decline in the proportion of proliferative cells in a concentration dependent manner. At 10 μM, EGCG promoted cell differentiation, an effect not related with apoptosis or cytotoxicity. When 10 μM EGCG was instilled in corneal alkali burns in mice three times a day up to 21 days, EGCG significantly reduced corneal opacity and neovascularization. The improved clinical appearance of the cornea was associated to a controlled epithelial growth; epithelial morphology was similar to that observed in normal epithelium and contrasted with the hyperproliferative, desquamating epithelium observed in control burn wounds. EGCG reduced corneal, stromal and endothelial edema, and wound inflammation.

Conclusion

This work constitutes the first evidence for the use of EGCG in the acute phase of a corneal alkali burn, representing a possible novel alternative to improve patient outcomes as an add-on therapy.  相似文献   
89.
90.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号